Global RNAi for Therapeutic Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Page: 104

Published Date: 18 Mar 2023

Category: Medical Care

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Related Reports
Product Tags

Description

RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.

According to our (Global Info Research) latest study, the global RNAi for Therapeutic market size was valued at USD 181.1 million in 2022 and is forecast to a readjusted size of USD 2031.2 million by 2029 with a CAGR of 41.2% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

Global RNAi for Therapeutic key players include Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead, Dicerna Pharmaceuticals, Mirna Therapeutics, etc. Global top five manufacturers hold a share over 85%.

US is the largest market, with a share over 75%, followed by EU, which has a share about 3%.

In terms of product, siRNA is the largest segment, with a share over 55%. And in terms of application, the largest application is Cancer, followed by HBV, Cardiovascular, etc.

This report is a detailed and comprehensive analysis for global RNAi for Therapeutic market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:
Global RNAi for Therapeutic market size and forecasts, in consumption value ($ Million), 2018-2029
Global RNAi for Therapeutic market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global RNAi for Therapeutic market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global RNAi for Therapeutic market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for RNAi for Therapeutic
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global RNAi for Therapeutic market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead, Dicerna Pharmaceuticals and Mirna Therapeutics, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market segmentation
RNAi for Therapeutic market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
    siRNA
    miRNA
    shRNA

Market segment by Application
    Cancer
    Cardiovascular
    HBV
    Others

Market segment by players, this report covers
    Alnylam Pharmaceuticals
    Arbutus Biopharma (Tekmira)
    Arrowhead
    Dicerna Pharmaceuticals
    Mirna Therapeutics
    Quark Pharmaceuticals
    RXi Pharmaceuticals
    Silence Therapeutics
    Benitec Biopharma
    miRagen Therapeutics
    Sylentis
    Gradalis
    Sirnaomics
    Silenseed

Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
    South America (Brazil, Argentina and Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe RNAi for Therapeutic product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of RNAi for Therapeutic, with revenue, gross margin and global market share of RNAi for Therapeutic from 2018 to 2023.
Chapter 3, the RNAi for Therapeutic competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and RNAi for Therapeutic market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of RNAi for Therapeutic.
Chapter 13, to describe RNAi for Therapeutic research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of RNAi for Therapeutic
    1.2 Market Estimation Caveats and Base Year
    1.3 Classification of RNAi for Therapeutic by Type
        1.3.1 Overview: Global RNAi for Therapeutic Market Size by Type: 2018 Versus 2022 Versus 2029
        1.3.2 Global RNAi for Therapeutic Consumption Value Market Share by Type in 2022
        1.3.3 siRNA
        1.3.4 miRNA
        1.3.5 shRNA
    1.4 Global RNAi for Therapeutic Market by Application
        1.4.1 Overview: Global RNAi for Therapeutic Market Size by Application: 2018 Versus 2022 Versus 2029
        1.4.2 Cancer
        1.4.3 Cardiovascular
        1.4.4 HBV
        1.4.5 Others
    1.5 Global RNAi for Therapeutic Market Size & Forecast
    1.6 Global RNAi for Therapeutic Market Size and Forecast by Region
        1.6.1 Global RNAi for Therapeutic Market Size by Region: 2018 VS 2022 VS 2029
        1.6.2 Global RNAi for Therapeutic Market Size by Region, (2018-2029)
        1.6.3 North America RNAi for Therapeutic Market Size and Prospect (2018-2029)
        1.6.4 Europe RNAi for Therapeutic Market Size and Prospect (2018-2029)
        1.6.5 Asia-Pacific RNAi for Therapeutic Market Size and Prospect (2018-2029)
        1.6.6 South America RNAi for Therapeutic Market Size and Prospect (2018-2029)
        1.6.7 Middle East and Africa RNAi for Therapeutic Market Size and Prospect (2018-2029)

2 Company Profiles
    2.1 Alnylam Pharmaceuticals
        2.1.1 Alnylam Pharmaceuticals Details
        2.1.2 Alnylam Pharmaceuticals Major Business
        2.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Product and Solutions
        2.1.4 Alnylam Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
        2.1.5 Alnylam Pharmaceuticals Recent Developments and Future Plans
    2.2 Arbutus Biopharma (Tekmira)
        2.2.1 Arbutus Biopharma (Tekmira) Details
        2.2.2 Arbutus Biopharma (Tekmira) Major Business
        2.2.3 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Product and Solutions
        2.2.4 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
        2.2.5 Arbutus Biopharma (Tekmira) Recent Developments and Future Plans
    2.3 Arrowhead
        2.3.1 Arrowhead Details
        2.3.2 Arrowhead Major Business
        2.3.3 Arrowhead RNAi for Therapeutic Product and Solutions
        2.3.4 Arrowhead RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
        2.3.5 Arrowhead Recent Developments and Future Plans
    2.4 Dicerna Pharmaceuticals
        2.4.1 Dicerna Pharmaceuticals Details
        2.4.2 Dicerna Pharmaceuticals Major Business
        2.4.3 Dicerna Pharmaceuticals RNAi for Therapeutic Product and Solutions
        2.4.4 Dicerna Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
        2.4.5 Dicerna Pharmaceuticals Recent Developments and Future Plans
    2.5 Mirna Therapeutics
        2.5.1 Mirna Therapeutics Details
        2.5.2 Mirna Therapeutics Major Business
        2.5.3 Mirna Therapeutics RNAi for Therapeutic Product and Solutions
        2.5.4 Mirna Therapeutics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
        2.5.5 Mirna Therapeutics Recent Developments and Future Plans
    2.6 Quark Pharmaceuticals
        2.6.1 Quark Pharmaceuticals Details
        2.6.2 Quark Pharmaceuticals Major Business
        2.6.3 Quark Pharmaceuticals RNAi for Therapeutic Product and Solutions
        2.6.4 Quark Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
        2.6.5 Quark Pharmaceuticals Recent Developments and Future Plans
    2.7 RXi Pharmaceuticals
        2.7.1 RXi Pharmaceuticals Details
        2.7.2 RXi Pharmaceuticals Major Business
        2.7.3 RXi Pharmaceuticals RNAi for Therapeutic Product and Solutions
        2.7.4 RXi Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
        2.7.5 RXi Pharmaceuticals Recent Developments and Future Plans
    2.8 Silence Therapeutics
        2.8.1 Silence Therapeutics Details
        2.8.2 Silence Therapeutics Major Business
        2.8.3 Silence Therapeutics RNAi for Therapeutic Product and Solutions
        2.8.4 Silence Therapeutics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
        2.8.5 Silence Therapeutics Recent Developments and Future Plans
    2.9 Benitec Biopharma
        2.9.1 Benitec Biopharma Details
        2.9.2 Benitec Biopharma Major Business
        2.9.3 Benitec Biopharma RNAi for Therapeutic Product and Solutions
        2.9.4 Benitec Biopharma RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
        2.9.5 Benitec Biopharma Recent Developments and Future Plans
    2.10 miRagen Therapeutics
        2.10.1 miRagen Therapeutics Details
        2.10.2 miRagen Therapeutics Major Business
        2.10.3 miRagen Therapeutics RNAi for Therapeutic Product and Solutions
        2.10.4 miRagen Therapeutics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
        2.10.5 miRagen Therapeutics Recent Developments and Future Plans
    2.11 Sylentis
        2.11.1 Sylentis Details
        2.11.2 Sylentis Major Business
        2.11.3 Sylentis RNAi for Therapeutic Product and Solutions
        2.11.4 Sylentis RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
        2.11.5 Sylentis Recent Developments and Future Plans
    2.12 Gradalis
        2.12.1 Gradalis Details
        2.12.2 Gradalis Major Business
        2.12.3 Gradalis RNAi for Therapeutic Product and Solutions
        2.12.4 Gradalis RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
        2.12.5 Gradalis Recent Developments and Future Plans
    2.13 Sirnaomics
        2.13.1 Sirnaomics Details
        2.13.2 Sirnaomics Major Business
        2.13.3 Sirnaomics RNAi for Therapeutic Product and Solutions
        2.13.4 Sirnaomics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
        2.13.5 Sirnaomics Recent Developments and Future Plans
    2.14 Silenseed
        2.14.1 Silenseed Details
        2.14.2 Silenseed Major Business
        2.14.3 Silenseed RNAi for Therapeutic Product and Solutions
        2.14.4 Silenseed RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
        2.14.5 Silenseed Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global RNAi for Therapeutic Revenue and Share by Players (2018-2023)
    3.2 Market Share Analysis (2022)
        3.2.1 Market Share of RNAi for Therapeutic by Company Revenue
        3.2.2 Top 3 RNAi for Therapeutic Players Market Share in 2022
        3.2.3 Top 6 RNAi for Therapeutic Players Market Share in 2022
    3.3 RNAi for Therapeutic Market: Overall Company Footprint Analysis
        3.3.1 RNAi for Therapeutic Market: Region Footprint
        3.3.2 RNAi for Therapeutic Market: Company Product Type Footprint
        3.3.3 RNAi for Therapeutic Market: Company Product Application Footprint
    3.4 New Market Entrants and Barriers to Market Entry
    3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type
    4.1 Global RNAi for Therapeutic Consumption Value and Market Share by Type (2018-2023)
    4.2 Global RNAi for Therapeutic Market Forecast by Type (2024-2029)

5 Market Size Segment by Application
    5.1 Global RNAi for Therapeutic Consumption Value Market Share by Application (2018-2023)
    5.2 Global RNAi for Therapeutic Market Forecast by Application (2024-2029)

6 North America
    6.1 North America RNAi for Therapeutic Consumption Value by Type (2018-2029)
    6.2 North America RNAi for Therapeutic Consumption Value by Application (2018-2029)
    6.3 North America RNAi for Therapeutic Market Size by Country
        6.3.1 North America RNAi for Therapeutic Consumption Value by Country (2018-2029)
        6.3.2 United States RNAi for Therapeutic Market Size and Forecast (2018-2029)
        6.3.3 Canada RNAi for Therapeutic Market Size and Forecast (2018-2029)
        6.3.4 Mexico RNAi for Therapeutic Market Size and Forecast (2018-2029)

7 Europe
    7.1 Europe RNAi for Therapeutic Consumption Value by Type (2018-2029)
    7.2 Europe RNAi for Therapeutic Consumption Value by Application (2018-2029)
    7.3 Europe RNAi for Therapeutic Market Size by Country
        7.3.1 Europe RNAi for Therapeutic Consumption Value by Country (2018-2029)
        7.3.2 Germany RNAi for Therapeutic Market Size and Forecast (2018-2029)
        7.3.3 France RNAi for Therapeutic Market Size and Forecast (2018-2029)
        7.3.4 United Kingdom RNAi for Therapeutic Market Size and Forecast (2018-2029)
        7.3.5 Russia RNAi for Therapeutic Market Size and Forecast (2018-2029)
        7.3.6 Italy RNAi for Therapeutic Market Size and Forecast (2018-2029)

8 Asia-Pacific
    8.1 Asia-Pacific RNAi for Therapeutic Consumption Value by Type (2018-2029)
    8.2 Asia-Pacific RNAi for Therapeutic Consumption Value by Application (2018-2029)
    8.3 Asia-Pacific RNAi for Therapeutic Market Size by Region
        8.3.1 Asia-Pacific RNAi for Therapeutic Consumption Value by Region (2018-2029)
        8.3.2 China RNAi for Therapeutic Market Size and Forecast (2018-2029)
        8.3.3 Japan RNAi for Therapeutic Market Size and Forecast (2018-2029)
        8.3.4 South Korea RNAi for Therapeutic Market Size and Forecast (2018-2029)
        8.3.5 India RNAi for Therapeutic Market Size and Forecast (2018-2029)
        8.3.6 Southeast Asia RNAi for Therapeutic Market Size and Forecast (2018-2029)
        8.3.7 Australia RNAi for Therapeutic Market Size and Forecast (2018-2029)

9 South America
    9.1 South America RNAi for Therapeutic Consumption Value by Type (2018-2029)
    9.2 South America RNAi for Therapeutic Consumption Value by Application (2018-2029)
    9.3 South America RNAi for Therapeutic Market Size by Country
        9.3.1 South America RNAi for Therapeutic Consumption Value by Country (2018-2029)
        9.3.2 Brazil RNAi for Therapeutic Market Size and Forecast (2018-2029)
        9.3.3 Argentina RNAi for Therapeutic Market Size and Forecast (2018-2029)

10 Middle East & Africa
    10.1 Middle East & Africa RNAi for Therapeutic Consumption Value by Type (2018-2029)
    10.2 Middle East & Africa RNAi for Therapeutic Consumption Value by Application (2018-2029)
    10.3 Middle East & Africa RNAi for Therapeutic Market Size by Country
        10.3.1 Middle East & Africa RNAi for Therapeutic Consumption Value by Country (2018-2029)
        10.3.2 Turkey RNAi for Therapeutic Market Size and Forecast (2018-2029)
        10.3.3 Saudi Arabia RNAi for Therapeutic Market Size and Forecast (2018-2029)
        10.3.4 UAE RNAi for Therapeutic Market Size and Forecast (2018-2029)

11 Market Dynamics
    11.1 RNAi for Therapeutic Market Drivers
    11.2 RNAi for Therapeutic Market Restraints
    11.3 RNAi for Therapeutic Trends Analysis
    11.4 Porters Five Forces Analysis
        11.4.1 Threat of New Entrants
        11.4.2 Bargaining Power of Suppliers
        11.4.3 Bargaining Power of Buyers
        11.4.4 Threat of Substitutes
        11.4.5 Competitive Rivalry
    11.5 Influence of COVID-19 and Russia-Ukraine War
        11.5.1 Influence of COVID-19
        11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis
    12.1 RNAi for Therapeutic Industry Chain
    12.2 RNAi for Therapeutic Upstream Analysis
    12.3 RNAi for Therapeutic Midstream Analysis
    12.4 RNAi for Therapeutic Downstream Analysis

13 Research Findings and Conclusion

14 Appendix
    14.1 Methodology
    14.2 Research Process and Data Source
    14.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global RNAi for Therapeutic Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Table 2. Global RNAi for Therapeutic Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
    Table 3. Global RNAi for Therapeutic Consumption Value by Region (2018-2023) & (USD Million)
    Table 4. Global RNAi for Therapeutic Consumption Value by Region (2024-2029) & (USD Million)
    Table 5. Alnylam Pharmaceuticals Company Information, Head Office, and Major Competitors
    Table 6. Alnylam Pharmaceuticals Major Business
    Table 7. Alnylam Pharmaceuticals RNAi for Therapeutic Product and Solutions
    Table 8. Alnylam Pharmaceuticals RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 9. Alnylam Pharmaceuticals Recent Developments and Future Plans
    Table 10. Arbutus Biopharma (Tekmira) Company Information, Head Office, and Major Competitors
    Table 11. Arbutus Biopharma (Tekmira) Major Business
    Table 12. Arbutus Biopharma (Tekmira) RNAi for Therapeutic Product and Solutions
    Table 13. Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 14. Arbutus Biopharma (Tekmira) Recent Developments and Future Plans
    Table 15. Arrowhead Company Information, Head Office, and Major Competitors
    Table 16. Arrowhead Major Business
    Table 17. Arrowhead RNAi for Therapeutic Product and Solutions
    Table 18. Arrowhead RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 19. Arrowhead Recent Developments and Future Plans
    Table 20. Dicerna Pharmaceuticals Company Information, Head Office, and Major Competitors
    Table 21. Dicerna Pharmaceuticals Major Business
    Table 22. Dicerna Pharmaceuticals RNAi for Therapeutic Product and Solutions
    Table 23. Dicerna Pharmaceuticals RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 24. Dicerna Pharmaceuticals Recent Developments and Future Plans
    Table 25. Mirna Therapeutics Company Information, Head Office, and Major Competitors
    Table 26. Mirna Therapeutics Major Business
    Table 27. Mirna Therapeutics RNAi for Therapeutic Product and Solutions
    Table 28. Mirna Therapeutics RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 29. Mirna Therapeutics Recent Developments and Future Plans
    Table 30. Quark Pharmaceuticals Company Information, Head Office, and Major Competitors
    Table 31. Quark Pharmaceuticals Major Business
    Table 32. Quark Pharmaceuticals RNAi for Therapeutic Product and Solutions
    Table 33. Quark Pharmaceuticals RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 34. Quark Pharmaceuticals Recent Developments and Future Plans
    Table 35. RXi Pharmaceuticals Company Information, Head Office, and Major Competitors
    Table 36. RXi Pharmaceuticals Major Business
    Table 37. RXi Pharmaceuticals RNAi for Therapeutic Product and Solutions
    Table 38. RXi Pharmaceuticals RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 39. RXi Pharmaceuticals Recent Developments and Future Plans
    Table 40. Silence Therapeutics Company Information, Head Office, and Major Competitors
    Table 41. Silence Therapeutics Major Business
    Table 42. Silence Therapeutics RNAi for Therapeutic Product and Solutions
    Table 43. Silence Therapeutics RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 44. Silence Therapeutics Recent Developments and Future Plans
    Table 45. Benitec Biopharma Company Information, Head Office, and Major Competitors
    Table 46. Benitec Biopharma Major Business
    Table 47. Benitec Biopharma RNAi for Therapeutic Product and Solutions
    Table 48. Benitec Biopharma RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 49. Benitec Biopharma Recent Developments and Future Plans
    Table 50. miRagen Therapeutics Company Information, Head Office, and Major Competitors
    Table 51. miRagen Therapeutics Major Business
    Table 52. miRagen Therapeutics RNAi for Therapeutic Product and Solutions
    Table 53. miRagen Therapeutics RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 54. miRagen Therapeutics Recent Developments and Future Plans
    Table 55. Sylentis Company Information, Head Office, and Major Competitors
    Table 56. Sylentis Major Business
    Table 57. Sylentis RNAi for Therapeutic Product and Solutions
    Table 58. Sylentis RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 59. Sylentis Recent Developments and Future Plans
    Table 60. Gradalis Company Information, Head Office, and Major Competitors
    Table 61. Gradalis Major Business
    Table 62. Gradalis RNAi for Therapeutic Product and Solutions
    Table 63. Gradalis RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 64. Gradalis Recent Developments and Future Plans
    Table 65. Sirnaomics Company Information, Head Office, and Major Competitors
    Table 66. Sirnaomics Major Business
    Table 67. Sirnaomics RNAi for Therapeutic Product and Solutions
    Table 68. Sirnaomics RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 69. Sirnaomics Recent Developments and Future Plans
    Table 70. Silenseed Company Information, Head Office, and Major Competitors
    Table 71. Silenseed Major Business
    Table 72. Silenseed RNAi for Therapeutic Product and Solutions
    Table 73. Silenseed RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 74. Silenseed Recent Developments and Future Plans
    Table 75. Global RNAi for Therapeutic Revenue (USD Million) by Players (2018-2023)
    Table 76. Global RNAi for Therapeutic Revenue Share by Players (2018-2023)
    Table 77. Breakdown of RNAi for Therapeutic by Company Type (Tier 1, Tier 2, and Tier 3)
    Table 78. Market Position of Players in RNAi for Therapeutic, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
    Table 79. Head Office of Key RNAi for Therapeutic Players
    Table 80. RNAi for Therapeutic Market: Company Product Type Footprint
    Table 81. RNAi for Therapeutic Market: Company Product Application Footprint
    Table 82. RNAi for Therapeutic New Market Entrants and Barriers to Market Entry
    Table 83. RNAi for Therapeutic Mergers, Acquisition, Agreements, and Collaborations
    Table 84. Global RNAi for Therapeutic Consumption Value (USD Million) by Type (2018-2023)
    Table 85. Global RNAi for Therapeutic Consumption Value Share by Type (2018-2023)
    Table 86. Global RNAi for Therapeutic Consumption Value Forecast by Type (2024-2029)
    Table 87. Global RNAi for Therapeutic Consumption Value by Application (2018-2023)
    Table 88. Global RNAi for Therapeutic Consumption Value Forecast by Application (2024-2029)
    Table 89. North America RNAi for Therapeutic Consumption Value by Type (2018-2023) & (USD Million)
    Table 90. North America RNAi for Therapeutic Consumption Value by Type (2024-2029) & (USD Million)
    Table 91. North America RNAi for Therapeutic Consumption Value by Application (2018-2023) & (USD Million)
    Table 92. North America RNAi for Therapeutic Consumption Value by Application (2024-2029) & (USD Million)
    Table 93. North America RNAi for Therapeutic Consumption Value by Country (2018-2023) & (USD Million)
    Table 94. North America RNAi for Therapeutic Consumption Value by Country (2024-2029) & (USD Million)
    Table 95. Europe RNAi for Therapeutic Consumption Value by Type (2018-2023) & (USD Million)
    Table 96. Europe RNAi for Therapeutic Consumption Value by Type (2024-2029) & (USD Million)
    Table 97. Europe RNAi for Therapeutic Consumption Value by Application (2018-2023) & (USD Million)
    Table 98. Europe RNAi for Therapeutic Consumption Value by Application (2024-2029) & (USD Million)
    Table 99. Europe RNAi for Therapeutic Consumption Value by Country (2018-2023) & (USD Million)
    Table 100. Europe RNAi for Therapeutic Consumption Value by Country (2024-2029) & (USD Million)
    Table 101. Asia-Pacific RNAi for Therapeutic Consumption Value by Type (2018-2023) & (USD Million)
    Table 102. Asia-Pacific RNAi for Therapeutic Consumption Value by Type (2024-2029) & (USD Million)
    Table 103. Asia-Pacific RNAi for Therapeutic Consumption Value by Application (2018-2023) & (USD Million)
    Table 104. Asia-Pacific RNAi for Therapeutic Consumption Value by Application (2024-2029) & (USD Million)
    Table 105. Asia-Pacific RNAi for Therapeutic Consumption Value by Region (2018-2023) & (USD Million)
    Table 106. Asia-Pacific RNAi for Therapeutic Consumption Value by Region (2024-2029) & (USD Million)
    Table 107. South America RNAi for Therapeutic Consumption Value by Type (2018-2023) & (USD Million)
    Table 108. South America RNAi for Therapeutic Consumption Value by Type (2024-2029) & (USD Million)
    Table 109. South America RNAi for Therapeutic Consumption Value by Application (2018-2023) & (USD Million)
    Table 110. South America RNAi for Therapeutic Consumption Value by Application (2024-2029) & (USD Million)
    Table 111. South America RNAi for Therapeutic Consumption Value by Country (2018-2023) & (USD Million)
    Table 112. South America RNAi for Therapeutic Consumption Value by Country (2024-2029) & (USD Million)
    Table 113. Middle East & Africa RNAi for Therapeutic Consumption Value by Type (2018-2023) & (USD Million)
    Table 114. Middle East & Africa RNAi for Therapeutic Consumption Value by Type (2024-2029) & (USD Million)
    Table 115. Middle East & Africa RNAi for Therapeutic Consumption Value by Application (2018-2023) & (USD Million)
    Table 116. Middle East & Africa RNAi for Therapeutic Consumption Value by Application (2024-2029) & (USD Million)
    Table 117. Middle East & Africa RNAi for Therapeutic Consumption Value by Country (2018-2023) & (USD Million)
    Table 118. Middle East & Africa RNAi for Therapeutic Consumption Value by Country (2024-2029) & (USD Million)
    Table 119. RNAi for Therapeutic Raw Material
    Table 120. Key Suppliers of RNAi for Therapeutic Raw Materials
List of Figures
    Figure 1. RNAi for Therapeutic Picture
    Figure 2. Global RNAi for Therapeutic Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 3. Global RNAi for Therapeutic Consumption Value Market Share by Type in 2022
    Figure 4. siRNA
    Figure 5. miRNA
    Figure 6. shRNA
    Figure 7. Global RNAi for Therapeutic Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 8. RNAi for Therapeutic Consumption Value Market Share by Application in 2022
    Figure 9. Cancer Picture
    Figure 10. Cardiovascular Picture
    Figure 11. HBV Picture
    Figure 12. Others Picture
    Figure 13. Global RNAi for Therapeutic Consumption Value, (USD Million): 2018 & 2022 & 2029
    Figure 14. Global RNAi for Therapeutic Consumption Value and Forecast (2018-2029) & (USD Million)
    Figure 15. Global Market RNAi for Therapeutic Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
    Figure 16. Global RNAi for Therapeutic Consumption Value Market Share by Region (2018-2029)
    Figure 17. Global RNAi for Therapeutic Consumption Value Market Share by Region in 2022
    Figure 18. North America RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
    Figure 19. Europe RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
    Figure 20. Asia-Pacific RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
    Figure 21. South America RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
    Figure 22. Middle East and Africa RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
    Figure 23. Global RNAi for Therapeutic Revenue Share by Players in 2022
    Figure 24. RNAi for Therapeutic Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
    Figure 25. Global Top 3 Players RNAi for Therapeutic Market Share in 2022
    Figure 26. Global Top 6 Players RNAi for Therapeutic Market Share in 2022
    Figure 27. Global RNAi for Therapeutic Consumption Value Share by Type (2018-2023)
    Figure 28. Global RNAi for Therapeutic Market Share Forecast by Type (2024-2029)
    Figure 29. Global RNAi for Therapeutic Consumption Value Share by Application (2018-2023)
    Figure 30. Global RNAi for Therapeutic Market Share Forecast by Application (2024-2029)
    Figure 31. North America RNAi for Therapeutic Consumption Value Market Share by Type (2018-2029)
    Figure 32. North America RNAi for Therapeutic Consumption Value Market Share by Application (2018-2029)
    Figure 33. North America RNAi for Therapeutic Consumption Value Market Share by Country (2018-2029)
    Figure 34. United States RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
    Figure 35. Canada RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
    Figure 36. Mexico RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
    Figure 37. Europe RNAi for Therapeutic Consumption Value Market Share by Type (2018-2029)
    Figure 38. Europe RNAi for Therapeutic Consumption Value Market Share by Application (2018-2029)
    Figure 39. Europe RNAi for Therapeutic Consumption Value Market Share by Country (2018-2029)
    Figure 40. Germany RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
    Figure 41. France RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
    Figure 42. United Kingdom RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
    Figure 43. Russia RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
    Figure 44. Italy RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
    Figure 45. Asia-Pacific RNAi for Therapeutic Consumption Value Market Share by Type (2018-2029)
    Figure 46. Asia-Pacific RNAi for Therapeutic Consumption Value Market Share by Application (2018-2029)
    Figure 47. Asia-Pacific RNAi for Therapeutic Consumption Value Market Share by Region (2018-2029)
    Figure 48. China RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
    Figure 49. Japan RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
    Figure 50. South Korea RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
    Figure 51. India RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
    Figure 52. Southeast Asia RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
    Figure 53. Australia RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
    Figure 54. South America RNAi for Therapeutic Consumption Value Market Share by Type (2018-2029)
    Figure 55. South America RNAi for Therapeutic Consumption Value Market Share by Application (2018-2029)
    Figure 56. South America RNAi for Therapeutic Consumption Value Market Share by Country (2018-2029)
    Figure 57. Brazil RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
    Figure 58. Argentina RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
    Figure 59. Middle East and Africa RNAi for Therapeutic Consumption Value Market Share by Type (2018-2029)
    Figure 60. Middle East and Africa RNAi for Therapeutic Consumption Value Market Share by Application (2018-2029)
    Figure 61. Middle East and Africa RNAi for Therapeutic Consumption Value Market Share by Country (2018-2029)
    Figure 62. Turkey RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
    Figure 63. Saudi Arabia RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
    Figure 64. UAE RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
    Figure 65. RNAi for Therapeutic Market Drivers
    Figure 66. RNAi for Therapeutic Market Restraints
    Figure 67. RNAi for Therapeutic Market Trends
    Figure 68. Porters Five Forces Analysis
    Figure 69. Manufacturing Cost Structure Analysis of RNAi for Therapeutic in 2022
    Figure 70. Manufacturing Process Analysis of RNAi for Therapeutic
    Figure 71. RNAi for Therapeutic Industrial Chain
    Figure 72. Methodology
    Figure 73. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Related Reports

Global RNAi for Therapeutic Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Global RNAi for Therapeutic Market 2024 by Company, Regions, Type and Application, Forecast to 2030

date 02 Jan 2024

date Medical Care

According to our (Global Info Research) latest study, the global RNAi for Therapeutic market size was valued at USD 181.1 million in 2023 and is forecast to a readjusted size of USD 2031.2 million by 2030 with a CAGR of 41.2% during review period.

Global RNAi for Therapeutic Supply, Demand and Key Producers, 2024-2030

Global RNAi for Therapeutic Supply, Demand and Key Producers, 2024-2030

date 20 Feb 2024

date Medical Care

The global RNAi for Therapeutic market size is expected to reach $ 2031.2 million by 2030, rising at a market growth of 41.2% CAGR during the forecast period (2024-2030).

Product Tags

RNAi for Therapeutic

Organ Rejection Prophylaxis Treatment

Biologics Analytical Services

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>